Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- Estimated Glomerular Filtration Rate and Prognosis in Heart FailureJACC, 2012
- Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and CancerStem Cells, 2011
- Circulating neprilysin clears brain amyloidMolecular and Cellular Neuroscience, 2010
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac DamageClinical Chemistry, 2008
- Stimulated Release of Endothelin-converting Enzyme is Simultaneous with Tissue-type Plasminogen Activator and Decrease in Coronary Heart DiseaseScandinavian Cardiovascular Journal, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon 1 1Edited by R. HuberJournal of Molecular Biology, 2000
- Molecular cloning and amino acid sequence of human enkephalinase (neutral endopeptidase)FEBS Letters, 1988